Alzheimer’s disease affects millions of older adults in the United States, with cases expected to nearly double by 2060. Early detection is crucial as it enables patients and caregivers to access support services, plan care proactively, and consider emerging treatments that may slow disease progression1 2. However, diagnosis remains challenging due to underdiagnosis and the complexity of testing options. Recent advances in blood biomarker tests offer new possibilities for earlier and less invasive detection, complementing traditional cognitive screening methods3 4.
Cognitive Screening for Older Adults
Cognitive screening involves brief tests designed to detect signs of memory loss or cognitive decline that may indicate Alzheimer’s disease or other dementias. Awareness and use of cognitive screening among older adults vary widely. Approximately 70% of adults aged 65 and older report some familiarity with cognitive screening, with 30% being very familiar and 40% somewhat familiar3 . Despite this, about 30% of older adults report no familiarity with such screening3 .
In practice, only around 41% of older adults have ever undergone cognitive screening, indicating a gap between awareness and actual testing3 . Screening rates also differ by demographic factors; for example, Hispanic older adults have lower rates of cognitive screening compared to non-Hispanic White and Black adults5 . This disparity highlights the need for targeted education and outreach to improve screening access and uptake in diverse populations5 .
Older adults who serve as caregivers for people with dementia are slightly more likely to undergo cognitive screening themselves, but the increase is modest despite their elevated risk of cognitive impairment6 . Factors influencing screening include age, race, and healthcare access, while sex and income appear less associated with screening rates6 .
Cognitive screening is typically conducted during routine healthcare visits and may include brief assessments of memory, attention, language, and problem-solving skills. These tests are valuable for identifying individuals who may need further evaluation but are not definitive for Alzheimer’s diagnosis. They serve as an initial step to prompt more comprehensive clinical assessments4 .
List: Key Points About Cognitive Screening in Older Adults
- About 70% of older adults report some familiarity with cognitive screening3 .
- Only 41% have ever undergone cognitive screening3 .
- Hispanic older adults have lower screening rates than other racial groups5 .
- Dementia caregivers are marginally more likely to be screened than non-caregivers6 .
- Screening is a first step, not a definitive diagnosis, and requires follow-up evaluation4 .
“Today marks another important step in Alzheimer’s disease diagnosis. For too long Americans have struggled to get a simple and accurate diagnosis; with today’s action by the FDA we are hopeful it will be easier for more individuals to receive an accurate diagnosis earlier.”
— Maria C. Carrillo, Ph.D., Alzheimer’s Association7
Biomarker Tests for Alzheimer's Detection
Biomarker tests detect biological indicators of Alzheimer’s disease, such as amyloid-beta plaques and tau protein tangles, which are hallmarks of the disease. Traditionally, these biomarkers have been assessed through cerebrospinal fluid (CSF) analysis obtained via lumbar puncture or through positron emission tomography (PET) brain imaging4 . While accurate, these methods are invasive, expensive, and not widely accessible.
Recent advances have led to the development and FDA approval of blood-based biomarker tests that measure amyloid-beta and phosphorylated tau (p-tau) proteins in plasma. These blood tests offer a less invasive, more scalable option for detecting Alzheimer’s pathology3 47. For example, the Lumipulse test measures the ratio of pTau217 to amyloid-beta 1-42 and has demonstrated high accuracy in symptomatic adults aged 50 and older7 .
Despite their novelty, awareness of blood biomarker tests among older adults is surprisingly high, with about 20% reporting familiarity, although fewer than 1% have undergone such testing3 . Experts caution that these tests are intended to complement, not replace, clinical evaluation and history-taking4 .
Blood biomarker tests have several advantages:
- They are relatively simple and inexpensive compared to PET scans and lumbar punctures8 .
- They can help differentiate Alzheimer’s disease from other causes of cognitive decline8 .
- They may facilitate earlier diagnosis, potentially years before symptoms become severe8 .
However, interpretation of blood biomarker results requires caution. Positive results indicate increased risk but do not guarantee progression to dementia, especially in asymptomatic individuals8 . False positives and negatives can occur, and factors such as kidney disease may affect biomarker levels8 . Additionally, some studies suggest variability in test accuracy across racial groups, with lower accuracy reported in Black patients in certain cohorts8 .
Blood biomarker testing is currently recommended primarily for symptomatic individuals who have undergone cognitive assessment. In such cases, blood tests can confirm diagnosis and guide treatment decisions, potentially reducing the need for more invasive tests7 4.
Early diagnosis of Alzheimer’s disease is vital for enabling patients and caregivers to plan for the future and access emerging treatments. However, the complexity of interpreting biomarker tests and the limited efficacy of current therapies make early intervention a nuanced challenge. 248
| Biomarker Test Type | Method | Advantages | Limitations |
|---|---|---|---|
| Cerebrospinal Fluid (CSF) | Lumbar puncture | Established, accurate | Invasive, requires specialist |
| PET Imaging | Brain scan | Visualizes amyloid and tau plaques | Expensive, limited availability |
| Blood Biomarker Tests | Blood draw (e.g., Lumipulse) | Less invasive, scalable | Newer, interpretation challenges |
List: Facts About Blood Biomarker Testing
- Blood tests detect amyloid-beta and tau proteins linked to Alzheimer’s3 .
- Only about 20% of older adults are aware of blood biomarker tests3 .
- Less than 1% of older adults have undergone blood biomarker testing3 .
- Blood tests complement but do not replace clinical evaluation4 .
- FDA-approved blood tests are currently for symptomatic adults aged 50+ 7.
“Numerous research studies have shown that these blood signatures have high concordance. They agree really well with the gold standard biomarkers of Alzheimer’s disease, which we have been using in specialized settings for many years.”
— Ashvini Keshavan, University College London9
Early Intervention Challenges and Possibilities
Early diagnosis of Alzheimer’s disease offers important benefits, including the ability for patients and caregivers to plan care, make safety decisions, and access emerging treatments and clinical trials2 4. However, early intervention remains complex due to limitations in diagnostic accuracy and treatment options.
No diagnostic test for Alzheimer’s is 100% accurate; false positives and negatives can occur with both cognitive screening and biomarker testing4 . Clinical evaluation, including detailed history, physical examination, and informant reports from family or caregivers, remains the cornerstone of diagnosis4 . Patients may lack insight into their cognitive decline, making collateral history essential4 .
Biomarker tests serve as valuable tools to confirm diagnosis after initial clinical assessment but should not be used in isolation4 . Screening should be linked to actionable steps that benefit patients and families, such as safety planning for driving and living arrangements, and discussions about treatment options4 .
Current therapies, including recently approved monoclonal antibodies targeting amyloid plaques, may modestly slow disease progression but do not cure or reverse Alzheimer’s disease2 . These treatments carry risks such as brain swelling and hemorrhage, requiring careful patient selection and monitoring2 . Early detection enables timely enrollment in clinical trials and access to supportive services2 .
💡 Did You Know? Alzheimer disease and related cognitive impairments are often underdiagnosed, undertreated, and undermanaged, limiting opportunities for timely intervention and optimal patient outcomes10 .
Lifestyle changes like improved diet, exercise, and social engagement may help maintain brain health but have limited evidence in altering amyloid or tau pathology8 . The interpretation of biomarker tests in asymptomatic individuals is challenging, as positive results do not reliably predict who will develop clinical symptoms8 .
List: Challenges and Considerations in Early Intervention
- No test is fully accurate; clinical context is essential4 .
- Informant reports are critical due to possible patient unawareness4 .
- Early diagnosis allows for care planning and safety interventions2 4.
- Approved treatments modestly slow progression but carry risks2 .
- Blood biomarker tests are not recommended for asymptomatic individuals without cognitive impairment8 .
